ALLO

Allogene Therapeutics

Fundamental data last updated:April 13, 2026

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

05/12/26

Business Summary

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic cell therapies, particularly in oncology. Its model centers on investing heavily in R&D to advance engineered cell therapies through clinical trials with the goal of achieving regulatory approval and eventual commercialization. Cash generation, when it occurs, would come from approved therapy sales or strategic licensing partnerships, but at present the company operates in an investment phase with negative earnings. The moat, if realized, would stem from proprietary cell therapy platforms, manufacturing know-how, and clinical data that create barriers to replication in a complex and highly regulated therapeutic category.

VALUATION

P/E

-

Market Cap ($M USD)

$663

Forward P/E

-

PEG

-

PRICE TO SALES

-

PRICE TO BOOK

2.3

EV / EBITDA

-2.8

5-Year Average P/E

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$0.87

Next Year EPS Growth Estimate

-$0.75

Next Year Revenue Growth Estimate

-

Return on Equity (ROE)

-65.20%

Operating Margin

-

Debt-to-Equity

0.3

Piotroski F-Score

2

Altman Z-Score

-4.5

Return on Invested Capital (ROIC)

-47.10%%

Current Ratio

7.9

Quick Ratio

Gainseekers Quantitative Analysis

Summary

ALLO screens as a distressed, cash-burning biotech with extreme financial fragility and no valuation anchor. With no P/E, no Forward P/E, and no PEG, the market has no earnings framework to discount—this is a pure balance-sheet and survival story. The Altman Z-Score of -4.5 signals severe financial distress risk, while ROIC at -47.10% and an operating margin of -65.20% confirm a business structurally destroying capital. At a $663M market cap and 2.3x price-to-book, the stock is not statistically cheap enough to compensate for the fundamental deterioration implied by a Piotroski F-Score of 2 and deeply negative profitability metrics. This is not a mispricing; it is a high-risk clinical-stage equity trading on optionality rather than fundamentals.

AI Exposure / Tech Reliance

As a Biotechnology company, ALLO operates in a sector that increasingly integrates AI into drug discovery and trial optimization, which can compress development timelines and improve capital efficiency. However, the financial metrics show no evidence yet of operating leverage or productivity gains translating into margins or returns. Until AI-driven efficiencies materially impact its -65.20% operating margin or -47.10% ROIC, technology exposure remains thematic rather than financially proven.

The Bull Case

A speculative bull case hinges on balance sheet flexibility and asymmetric upside optionality. The current ratio of 7.9 suggests strong short-term liquidity, meaning the company can fund operations in the near term despite heavy losses. Trading at 2.3x book with a depressed $663M market cap, investors are effectively paying for pipeline optionality rather than earnings power, and with EPS expected to improve from -2.8 to -0.87 next year, the rate of loss contraction could be material. If operating leverage emerges and capital efficiency improves from the current Piotroski F-Score of 2, even modest clinical progress could re-rate the equity sharply given how compressed sentiment appears.

The Bear Case

The bear case is overwhelming. An Altman Z-Score of -4.5 is deep in distress territory, and a Piotroski F-Score of 2 signals deteriorating financial quality across multiple dimensions. Operating margin at -65.20% and ROIC at -47.10% confirm systematic value destruction, while EPS of -2.8 with no P/E framework leaves investors without an earnings-based margin of safety. Sales Growth Next Year listed as -$0.75 suggests contraction rather than expansion, and the absence of profitability metrics such as Return on Equity or Debt/Equity transparency compounds uncertainty. This is a capital-consuming enterprise where dilution risk and balance sheet erosion remain structural threats.

Market Sentiment & Smart Money

Short Interest %

11.90%

Analyst Consensus

1.56

Average Analyst Price Target

$7.47

Institutional Ownership %

61.20%

1-Year Beta

2.58

Insider Buying % (6 Mo)

15.30%%

Distance to 52-Week High

92.20%%

Distance to 52-Week Low

315.50%%